ROR

亜型選択性的な製品

ROR製品

• All (22)
• ROR阻害剤 (3)
• ROR抗体(1)
• ROR作動薬(9)
• 新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S7076	T0901317	T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively. T0901317 is a dual inverse agonist of RORα and RORγ with Ki of 132 nM and 51 nM, respectively. T0901317 significantly suppresses cell proliferation and induces apoptosis.	J Anim Sci Biotechnol, 2024, 15(1):124 Front Immunol, 2022, 13:848367 J Anim Sci Biotechnol, 2022, 13(1):120
S5775	SR1078	SR1078, a synthetic ligand for RORα and RORγ, functions as a RORα/γ agonist.	Cell Death Dis, 2021, 12(3):247
S0094	SR 0987	SR 0987, a SR 1078 analog, is an agonist for T cell-specific RORγ (RORγt) with EC50 of 800 nM. SR 0987 represses PD-1, produces IL17 and is potential for the treatment of cancer.	Evid Based Complement Alternat Med, 2022, 2022:8315503
S3483	TMP778	TMP778 is a selective inhibitor of RORγt with an IC50 of 5 nM in the Fluorescence Resonance Energy Transfer (FRET) assay and an IC50 of 17 nM in the RORγ assay.
S6610	GSK2981278	GSK2981278 is a highly potent and selective inverse agonist for RORγ.
S8860	Cintirorgon (LYC-55716)	Cintirorgon (LYC-55716) is a selective, first-in-class, oral, small-molecule investigational agent that selectively activates RORγ.
E0326	S18-000003	S18-000003, a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt), with an IC50 of <30 μM towards human RORγt in competitive binding assays.
E0637	Cedirogant	Cedirogant (ABBV-157) is an orally active RORγt inverse agonist, can be used for psoriasis research.
S6724	SR1001	SR1001 is a RORα inverse agonist with Ki values of 172 nM and 111 nM for RORα and RORγ respectively.
S2654	Neoruscogenin	Neoruscogenin, a natural sapogenin isolated from R. rhizoma, is a potent and high-affinity agonist of RAR-related orphan receptor alpha (RORα or nuclear receptor NR1F1).
D4013	Zilovertamab vedotin	Zilovertamab vedotin (VLS-101, MK-2140) is an antibody-drug conjugate (ADC) composed of a humanised monoclonal antibody targeting ROR1 and the anti-mitotic cytotoxic agent monomethyl auristatin E (MMAE). It has potential for the treatment of lymphoid malignancies.
S2969	SR3335	SR3335 (ML-176) is a selective and inverse agonist of retinoic acid receptor-related receptor α (RORα) that directly binds to RORα with Ki of 220 nM.
A2366	Zilovertamab (Anti-ROR1)	Zilovertamab (Anti-ROR1) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling with potential antineoplastic activity. MW: 145.5 kD.
S7076	T0901317	T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively. T0901317 is a dual inverse agonist of RORα and RORγ with Ki of 132 nM and 51 nM, respectively. T0901317 significantly suppresses cell proliferation and induces apoptosis.	J Anim Sci Biotechnol, 2024, 15(1):124 Front Immunol, 2022, 13:848367 J Anim Sci Biotechnol, 2022, 13(1):120
S5775	SR1078	SR1078, a synthetic ligand for RORα and RORγ, functions as a RORα/γ agonist.	Cell Death Dis, 2021, 12(3):247
S0094	SR 0987	SR 0987, a SR 1078 analog, is an agonist for T cell-specific RORγ (RORγt) with EC50 of 800 nM. SR 0987 represses PD-1, produces IL17 and is potential for the treatment of cancer.	Evid Based Complement Alternat Med, 2022, 2022:8315503
S6610	GSK2981278	GSK2981278 is a highly potent and selective inverse agonist for RORγ.
S8860	Cintirorgon (LYC-55716)	Cintirorgon (LYC-55716) is a selective, first-in-class, oral, small-molecule investigational agent that selectively activates RORγ.
E0637	Cedirogant	Cedirogant (ABBV-157) is an orally active RORγt inverse agonist, can be used for psoriasis research.
S6724	SR1001	SR1001 is a RORα inverse agonist with Ki values of 172 nM and 111 nM for RORα and RORγ respectively.
S2654	Neoruscogenin	Neoruscogenin, a natural sapogenin isolated from R. rhizoma, is a potent and high-affinity agonist of RAR-related orphan receptor alpha (RORα or nuclear receptor NR1F1).
S2969	SR3335	SR3335 (ML-176) is a selective and inverse agonist of retinoic acid receptor-related receptor α (RORα) that directly binds to RORα with Ki of 220 nM.
S3483	TMP778	TMP778 is a selective inhibitor of RORγt with an IC50 of 5 nM in the Fluorescence Resonance Energy Transfer (FRET) assay and an IC50 of 17 nM in the RORγ assay.
E0326	S18-000003	S18-000003, a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt), with an IC50 of <30 μM towards human RORγt in competitive binding assays.
D4013	Zilovertamab vedotin	Zilovertamab vedotin (VLS-101, MK-2140) is an antibody-drug conjugate (ADC) composed of a humanised monoclonal antibody targeting ROR1 and the anti-mitotic cytotoxic agent monomethyl auristatin E (MMAE). It has potential for the treatment of lymphoid malignancies.
A2366	Zilovertamab (Anti-ROR1)	Zilovertamab (Anti-ROR1) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling with potential antineoplastic activity. MW: 145.5 kD.
S7076	T0901317	T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively. T0901317 is a dual inverse agonist of RORα and RORγ with Ki of 132 nM and 51 nM, respectively. T0901317 significantly suppresses cell proliferation and induces apoptosis.	J Anim Sci Biotechnol, 2024, 15(1):124 Front Immunol, 2022, 13:848367 J Anim Sci Biotechnol, 2022, 13(1):120
S5775	SR1078	SR1078, a synthetic ligand for RORα and RORγ, functions as a RORα/γ agonist.	Cell Death Dis, 2021, 12(3):247
S0094	SR 0987	SR 0987, a SR 1078 analog, is an agonist for T cell-specific RORγ (RORγt) with EC50 of 800 nM. SR 0987 represses PD-1, produces IL17 and is potential for the treatment of cancer.	Evid Based Complement Alternat Med, 2022, 2022:8315503
S6610	GSK2981278	GSK2981278 is a highly potent and selective inverse agonist for RORγ.
S8860	Cintirorgon (LYC-55716)	Cintirorgon (LYC-55716) is a selective, first-in-class, oral, small-molecule investigational agent that selectively activates RORγ.
E0637	Cedirogant	Cedirogant (ABBV-157) is an orally active RORγt inverse agonist, can be used for psoriasis research.
S6724	SR1001	SR1001 is a RORα inverse agonist with Ki values of 172 nM and 111 nM for RORα and RORγ respectively.
S2654	Neoruscogenin	Neoruscogenin, a natural sapogenin isolated from R. rhizoma, is a potent and high-affinity agonist of RAR-related orphan receptor alpha (RORα or nuclear receptor NR1F1).
S2969	SR3335	SR3335 (ML-176) is a selective and inverse agonist of retinoic acid receptor-related receptor α (RORα) that directly binds to RORα with Ki of 220 nM.